市場調查報告書

全球克陽性菌感染疾病市場:成長,趨勢,及預測

Gram-positive Bacterial Infections Market - Growth, Trends, and Forecast (2020 - 2025)

出版商 Mordor Intelligence LLP 商品編碼 921973
出版日期 內容資訊 英文 114 Pages
商品交期: 2-3個工作天內
價格
全球克陽性菌感染疾病市場:成長,趨勢,及預測 Gram-positive Bacterial Infections Market - Growth, Trends, and Forecast (2020 - 2025)
出版日期: 2020年01月01日內容資訊: 英文 114 Pages
簡介

本報告提供全球克陽性菌感染疾病市場的相關調查,提供市場機會和趨勢,成長及阻礙因素,各藥物類型·疾病·流通管道·地區的市場分析,競爭情形,主要企業的簡介等資訊。

目錄

第1章 簡介

  • 調查成果
  • 調查的前提條件
  • 調查範圍

第2章 調查方法

第3章 摘要整理

第4章 市場動態

  • 市場概況
  • 市場成長要素
    • 克陽性菌感染疾病的增加
    • 藥物核準的增加
  • 市場阻礙因素
    • 抗生素抗性
  • 波特的五力分析

第5章 市場區隔

  • 藥物各類型
    • β-內醯胺抗菌劑
    • Fluoroquinolones
    • 青霉素
    • 頭孢菌素
    • RNA免疫沉澱(RIP)
    • 疫苗
    • 其他
  • 各疾病
    • 肺炎
    • 敗血症
    • 咽頭炎
    • 抗藥性金黃色葡萄球菌(MRSA)感染疾病
    • 心內膜炎
    • 腦膜炎
    • 其他
  • 各流通管道
    • 醫院藥局
    • 零售藥局
    • 線上藥局
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東·非洲
    • 南美

第6章 競爭情形

  • 企業簡介
    • GlaxoSmithKline
    • Johnson & Johnson Inc.
    • Merck & Co. Inc.
    • Pfizer Inc.
    • AstraZeneca
    • Astellas Pharma Inc.
    • Novartis AG
    • Sanofi SA
    • Sun Pharmaceutical Industries Ltd.
    • Cipla

第7章 市場機會及今後趨勢

目錄
Product Code: 67445

Market Overview

The major factor driving the growth of the Gram-positive Bacterial Infections market is the increasing prevalence of the infections because of gram-positive bacteria. Pneumonia is a type of Gram-positive Bacterial Infection that affects the lungs. According to WHO, Pneumonia killed 808 694 children under the age of 5 in 2017, accounting for 15% of all deaths of children under five years old. Pneumonia affects children and families everywhere but is most prevalent in South Asia and Sub-Saharan Africa.

Additionally, increasing product approvals for the treatment of the infections, the rising development of Anti-MRSA drugs are also boosting the market growth globally. In October 2018, Paratek Pharmaceuticals, Inc. received U.S. FDA approval for its NUZYRA (Omadacycline)injection, for the treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI). However, antibiotic resistance is the major restraint that is hampering the growth of the market. With the emergence of multidrug-resistant bacteria, antibiotic resistance has become a major concern to global public health. Many antibiotics that have been used to treat infectious diseases are no longer effective, as the pathogens have become resistant to them.

Scope of the Report

Gram-positive bacteria are among the most common human pathogens associated with clinical infections, which range from mild skin infections to sepsis. Gram-positive Bacterial Infections include Virulence, Pathogenesis, Immune Response, Inflammatory Response, Drug Resistance. There are several classic gram-positive species that cause disease in humans. The most common organisms include Streptococcus, Staphylococcus, Enterococcus, Bacillus, etc.

Key Market Trends

Cephalosporins segment holds a significant market share

Cephalosporins are beta-lactam antibiotics that inhibit the synthesis of peptidoglycan, present in the cell wall of the bacteria. According to the World Health Organization (WHO), this group of antibiotics is considered as 'critically important to human medicine'.

The cephalosporins are indicated for the treatment of infections caused by Gram-positive bacteria in certain circumstances. These include selected patients with endocarditis, osteomyelitis, septic arthritis, and cellulitis. They are also used as alternatives to the penicillins in penicillin-allergic patients and for 'mixed' infections caused by Gram-positive organisms.

Cephalosporin has a large share in the antibiotics market, which is partly due to overprescription, and also due to the fact that it is the most widely explored family of antibiotics with over five generations of cephalosporins that have already been developed.

Additionally, the companies are involved in the strategic development of new products.

North America Dominates the Market

North America and Europe are the major markets in the Gram-positive Bacterial Infections globally, due to the high prevalence of various types of gram-positive bacterial infections and associated diseases. In the United States, antibiotic use among older adults increased, after insurance coverage was expanded through Medicare Part D, particularly, of broad-spectrum antibiotics. Increasing product launches are anticipated to drive the gram-positive bacterial infections market in the North America region. For instance, in March 2017, Pfizer launched a combination of Avibactam and Ceftazidime drug Zavicefta, for the treatment of intraabdominal infections.

Competitive Landscape

The gram-positive Bacterial Infections market is moderately competitive. The market is comprised of many small and large market players. Some of the market players are GlaxoSmithKline PLC, Merck & Co. Inc., Pfizer Inc., etc. among others.

Key developments in the market include: In June 2019, the U.S. Food and Drug Administration approved expanded use of Merck & Co Inc's antibiotic Zerbaxa to treat hospital-acquired pneumonia in patients 18 years and older.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 RisingPrevalence of Gram-positive Bacterial Infections
    • 4.2.2 Increasing Number of Drug Approvals
  • 4.3 Market Restraints
    • 4.3.1 Antibiotic Resistance
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Drug Type
    • 5.1.1 b-Lactam antimicrobials
    • 5.1.2 Fluoroquinolones
    • 5.1.3 Penicillin
    • 5.1.4 Cephalosporins
    • 5.1.5 RNA Immunoprecipitation (RIP)
    • 5.1.6 Vaccine
    • 5.1.7 Others Drugs
  • 5.2 By Disease
    • 5.2.1 Pneumonia
    • 5.2.2 Sepsis
    • 5.2.3 Pharyngitis
    • 5.2.4 Methicillin-resistant Staphylococcus aureus (MRSA) Infections
    • 5.2.5 Endocarditis
    • 5.2.6 Meningitis
    • 5.2.7 Other Diseases
  • 5.3 By Distribution Channel
    • 5.3.1 Hospital Pharmacies
    • 5.3.2 Retail Pharmacies
    • 5.3.3 Online Pharmacies
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East and Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle East and Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 GlaxoSmithKline
    • 6.1.2 Johnson & Johnson Inc.
    • 6.1.3 Merck & Co. Inc.
    • 6.1.4 Pfizer Inc.
    • 6.1.5 AstraZeneca
    • 6.1.6 Astellas Pharma Inc.
    • 6.1.7 Novartis AG
    • 6.1.8 Sanofi SA
    • 6.1.9 Sun Pharmaceutical Industries Ltd.
    • 6.1.10 Cipla

7 MARKET OPPORTUNITIES AND FUTURE TRENDS